The Antidiabetic Agent Acarbose Improves Anti-PD-1 and Rapamycin Efficacy in Preclinical Renal Cancer
Simple Summary
- Supplementary File 1:
PDF-Document (PDF, 1113 KiB)
Orlandella, R.M.; Turbitt, W.J.; Gibson, J.T.; Boi, S.K.; Li, P.; Smith, D.L., Jr.; Norian, L.A. The Antidiabetic Agent Acarbose Improves Anti-PD-1 and Rapamycin Efficacy in Preclinical Renal Cancer. Cancers 2020, 12, 2872. https://doi.org/10.3390/cancers12102872
Orlandella RM, Turbitt WJ, Gibson JT, Boi SK, Li P, Smith DL Jr., Norian LA. The Antidiabetic Agent Acarbose Improves Anti-PD-1 and Rapamycin Efficacy in Preclinical Renal Cancer. Cancers. 2020; 12(10):2872. https://doi.org/10.3390/cancers12102872
Chicago/Turabian StyleOrlandella, Rachael M., William J. Turbitt, Justin T. Gibson, Shannon K. Boi, Peng Li, Daniel L. Smith Jr., and Lyse A. Norian. 2020. "The Antidiabetic Agent Acarbose Improves Anti-PD-1 and Rapamycin Efficacy in Preclinical Renal Cancer" Cancers 12, no. 10: 2872. https://doi.org/10.3390/cancers12102872